Log In
Print this Print this

PF-05280602 (formerly CB 813d)

Also known as: CB 813

  Manage Alerts
Collapse Summary General Information
Company Catalyst Biosciences Inc.
DescriptionNext-generation Factor VIIa variant
Molecular Target Factor VIIa
Mechanism of ActionProcoagulant
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationHemophilia
Indication DetailsTreat hemophilia A or B
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today